• 1
    Kidney Disease Outcomes Quality Initiative Group. K/DOQI clinical practice guidelines for management of dyslipidemias in patients with kidney disease. Am J Kidney Dis. 2003;41(4 suppl 3):I–IV, S1S91.
  • 2
    Manjunath G, Tighiouart H, Coresh J, et al. Level of kidney function as a risk factor for cardiovascular outcomes in the elderly. Kidney Int. 2003;63:11211129.
  • 3
    Manjunath G, Tighiouart H, Ibrahim H, et al. Level of kidney function as a risk factor for atherosclerotic cardiovascular outcomes in the community. J Am Coll Cardiol. 2003;41: 4755.
  • 4
    Mann JF, Gerstein HC, Pogue J, et al. Renal insufficiency as a predictor of cardiovascular outcomes and the impact of ramipril: the HOPE randomized trial. Ann Intern Med. 2001;134:629636.
  • 5
    Herzog CA, Ma JZ, Collins AJ. Poor long-term survival after acute myocardial infarction among patients on long-term dialysis. N Engl J Med. 1998;339:799805.
  • 6
    Mishkel GJ, Varghese JJ, Moore AL, et al. Short- and long-term clinical outcomes of coronary drug-eluting stent recipients presenting with chronic renal disease. J Invasive Cardiol. 2007;19:331337.
  • 7
    Papafaklis MI, Naka KK, Papamichael ND, et al. The impact of renal function on the long-term clinical course of patients who underwent percutaneous coronary intervention. Catheter Cardiovasc Interv. 2007;69:189197.
  • 8
    Mueller C, Neumann FJ, Perruchoud AP, et al. Renal function and long term mortality after unstable angina/non-ST segment elevation myocardial infarction treated very early and predominantly with percutaneous coronary intervention. Heart. 2004;90:902907.
  • 9
    Gruberg L, Dangas G, Mehran R, et al. Clinical outcome following percutaneous coronary interventions in patients with chronic renal failure. Catheter Cardiovasc Interv. 2002;55:6672.
  • 10
    Blackman D, Pinto R, Ross J, et al. Impact of renal insufficiency on outcome after contemporary percutaneous coronary intervention. Am Heart J. 2006;151:146152.
  • 11
    Bhatt DL, Roe MT, Peterson ED, et al. Utilization of early invasive management strategies for high-risk patients with non–ST-segment elevation acute coronary syndromes. JAMA. 2004;292:20962104.
  • 12
    Astor BC, Muntner P, Levin A, et al. Association of kidney function with anemia: the Third National Health and Nutrition Examination Survey (1988–1994). Arch Intern Med. 2002;162:14011408.
  • 13
    Berger AK, Duval S, Krumholz HM. Aspirin, β-blocker, and angiotensin-converting enzyme inhibitor therapy in patients with end-stage renal disease and an acute myocardial infarction. J Am Coll Cardiol. 2003;42:201208.
  • 14
    Fox CS, Muntner P, Chen AY, et al. Use of evidence-based therapies in short-term outcomes of ST-segment elevation myocardial infarction and non–ST-segment elevation myocardial infarction in patients with chronic kidney disease: a report from the National Cardiovascular Data Acute Coronary Treatment and Intervention Outcomes Network registry. Circulation. 2010;121:357365.
  • 15
    Stenvinkel P, Alvestrand A. Inflammation in end-stage renal disease: sources, consequences, and therapy. Semin Dial. 2002;15:329337.
  • 16
    Himmelfarb J. Chronic kidney disease and the public health. JAMA. 2007;297:26302633.
  • 17
    Coca SG, Krumholz HM, Garg AX, et al. Underrepresentation of renal disease in randomized controlled trials of cardiovascular disease. JAMA. 2006;296:13771384.
  • 18
    LaBresh KA, Ellrodt AG, Gliklich R, et al. Get With the Guidelines for cardiovascular secondary prevention: pilot results. Arch Intern Med. 2004;164:203209.